Chromatin Bioscience Collaborates with Astellas to Advance Synthetic Promotor Development

Enhancing Biotechnology: Chromatin Bioscience's Collaboration with Astellas Pharma



Edinburgh, Scotland – April 14, 2025 – Chromatin Bioscience, a leader in the development of synthetic promoters and gene control systems, has officially announced a collaboration agreement with Astellas Pharma, a global biotechnology company. This partnership aims to leverage Chromatin's proprietary chromatinLENS platform to create cell-selective synthetic promoters tailored to Astellas' target profiles.

The designed promoters will facilitate highly precise and sustained gene expression within specific cell types, a crucial advancement in the field of biotechnology. Michael Roberts, the CEO and founder of Chromatin Bioscience, expressed his enthusiasm for this collaboration, noting, "We are excited to embark on this partnership with Astellas. We believe that the ability to precisely control gene expression is becoming increasingly essential for various applications in biotechnology. This collaboration underscores the growing interest in synthetic promoter technology as a key to developing targeted biological systems."

The chromatinLENS platform allows for the identification of gene regulatory elements from the dark genome, enabling the rational design of synthetic promoters tailored to specific applications. This technology can be applied across multiple sectors, including therapeutics, agricultural technology, industrial biotechnology, and bioprocessing.

Chromatin’s collaboration with Astellas not only highlights the potential of its chromatinLENS platform but marks another milestone in the company’s series of partnerships that are shaping its growth and influence in the biotechnology sector. By harnessing the power of synthetic biology, this partnership aims to propel innovations that could lead to new therapies and biotechnology solutions.

Moreover, the focus on synthetic promoters reflects a broader trend within the biotechnology field, where precision and specificity in gene regulation can transform the approach towards developing drugs and other biological products. Chromatin's synthetic promoters have become integral to a growing number of customer programs, which reinforces the demand and interest in their innovative capabilities.

For further insights and updates on Chromatin Bioscience’s recent collaborations and projects, you can visit their official website at www.chromatinbio.com.

Overall, the collaboration between Chromatin Bioscience and Astellas Pharma signals exciting times ahead for the field of biotechnology, as both companies work together to push the envelope of what is achievable through engineered gene control systems.

Topics Other)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.